Single-fraction SBRT is safe and effective in treating early stage, medically inoperable NSCLC, according to a ten-year retrospective study of 229 patients, the largest single-institution report to date. Gregory Videtic, MD, radiation oncologist at Cleveland Clinic Cancer Center, joins the Cancer Advances podcast to discuss the findings that were presented at the American Society for Radiation Oncology (ASTRO) annual meeting.